Literature DB >> 36002763

Preparation and pharmaceutical properties of Hangeshashinto oral ointment and its safety and efficacy in Syrian hamsters with 5-fluorouracil-induced oral mucositis.

Takashi Ogihara1,2, Masato Kagawa1,2, Rintarou Yamanaka1,2, Satoshi Imai1, Kotaro Itohara1, Daiki Hira1, Shunsaku Nakagawa1, Atsushi Yonezawa1,2, Michiho Ito3, Takayuki Nakagawa4, Tomohiro Terada1, Kazuo Matsubara1,5.   

Abstract

Chemotherapy-induced oral mucositis (COM) is a common adverse effect of cancer chemotherapy. Several clinical studies reported that repetitive use of mouthwashes containing 2.5-6.25% Hangeshashinto (HST), a Kampo formula, relieves COM, but the effect is insufficient. To solve this problem, we produced an oral ointment of 12% HST extract (considered quantitatively equivalent to 20% commercially available HST), which will increase the local concentrations of its active ingredients and prolong the contact time with COM. In this study, we evaluated the pharmaceutical properties (spreadability and stability) of HST oral ointment. In addition, its safety (oral mucosal irritation) and therapeutic effects on 5-fluorouracil-induced oral mucositis were evaluated in male Syrian hamsters. The HST ointment showed good spreadability and stability for more than 8 weeks at 4 °C. In the oral mucosal irritation test, topical application of HST ointment (0.2 g) three times per day for 14 days had no adverse effect on the oral mucosa of hamsters. In hamsters treated with 5-fluorouracil (60 mg/kg) twice, COM was induced by a submucosal injection of 5% acetic acid into the cheek pouch. When HST ointment (50 µg) was topically applied to the mucositis area once per day for 12 days, the area and macroscopic score of mucositis were significantly decreased, and the depth of the wound tended to be reduced compared with the lactose ointment-treated control animals. These findings suggest that HST oral ointment shows good properties in spreadability, stability, and safety, and elicits a therapeutic effect in an animal model of COM.
© 2022. The Author(s) under exclusive licence to The Japanese Society of Pharmacognosy.

Entities:  

Keywords:  5-fluorouracil; Chemotherapy-induced oral mucositis; Hamster; Hangeshashinto; Oral ointment

Year:  2022        PMID: 36002763     DOI: 10.1007/s11418-022-01645-y

Source DB:  PubMed          Journal:  J Nat Med        ISSN: 1340-3443            Impact factor:   3.192


  26 in total

Review 1.  Oral Pain in the Cancer Patient.

Authors:  Joel B Epstein; Christine Miaskowski
Journal:  J Natl Cancer Inst Monogr       Date:  2019-08-01

Review 2.  Pain mechanism of oral ulcerative mucositis and the therapeutic traditional herbal medicine hangeshashinto.

Authors:  Suzuro Hitomi; Izumi Ujihara; Kentaro Ono
Journal:  J Oral Biosci       Date:  2019-01-30

3.  Multitargeted effects of hangeshashinto for treatment of chemotherapy-induced oral mucositis on inducible prostaglandin E2 production in human oral keratinocytes.

Authors:  Toru Kono; Atsushi Kaneko; Chinami Matsumoto; Chika Miyagi; Katsuya Ohbuchi; Yasuharu Mizuhara; Kanako Miyano; Yasuhito Uezono
Journal:  Integr Cancer Ther       Date:  2014-02-04       Impact factor: 3.279

Review 4.  Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients.

Authors:  Deborah P Saunders; Joel B Epstein; Sharon Elad; Justin Allemano; Paolo Bossi; Marianne D van de Wetering; Nikhil G Rao; Carin Potting; Karis K Cheng; Annette Freidank; Michael T Brennan; Joanne Bowen; Kristopher Dennis; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2013-07-06       Impact factor: 3.603

5.  The traditional Japanese medicine hangeshashinto alleviates oral ulcer-induced pain in a rat model.

Authors:  Suzuro Hitomi; Kentaro Ono; Kiichiro Yamaguchi; Kiyoshi Terawaki; Ryota Imai; Kunitsugu Kubota; Yuji Omiya; Tomohisa Hattori; Yoshio Kase; Kiyotoshi Inenaga
Journal:  Arch Oral Biol       Date:  2016-02-03       Impact factor: 2.633

6.  Hangeshashinto (TJ-14) prevents radiation-induced mucositis by suppressing cyclooxygenase-2 expression and chemotaxis of inflammatory cells.

Authors:  D Kamide; T Yamashita; K Araki; M Tomifuji; A Shiotani
Journal:  Clin Transl Oncol       Date:  2017-05-17       Impact factor: 3.405

7.  The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis.

Authors:  Linda S Elting; Catherine Cooksley; Mark Chambers; Scott B Cantor; Ellen Manzullo; Edward B Rubenstein
Journal:  Cancer       Date:  2003-10-01       Impact factor: 6.860

Review 8.  Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements.

Authors:  Vitaliana De Sanctis; Paolo Bossi; Giuseppe Sanguineti; Fabio Trippa; Daris Ferrari; Almalina Bacigalupo; Carla Ida Ripamonti; Michela Buglione; Stefano Pergolizzi; Johannes A Langendjik; Barbara Murphy; Judith Raber-Durlacher; Elvio G Russi; Rajesh V Lalla
Journal:  Crit Rev Oncol Hematol       Date:  2016-02-01       Impact factor: 6.312

9.  Analysis of the antioxidative function of the radioprotective Japanese traditional (Kampo) medicine, hangeshashinto, in an aqueous phase.

Authors:  Chinami Matsumoto; Emiko Sekine-Suzuki; Minako Nyui; Megumi Ueno; Ikuo Nakanishi; Yuji Omiya; Masato Fukutake; Yoshio Kase; Ken-ichiro Matsumoto
Journal:  J Radiat Res       Date:  2015-04-16       Impact factor: 2.724

10.  Current Trends in Management of Oral Mucositis in Cancer Treatment

Authors:  Abhishek Shankar; Shubham Roy; Menal Bhandari; G K Rath; Aalekhya Sharma Biswas; Ravi Kanodia; Narayan Adhikari; Rashika Sachan
Journal:  Asian Pac J Cancer Prev       Date:  2017-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.